Clene insider reports December sales of common stock

Clene Inc. reported insider selling of common stock by a 10% owner in December 2025.

Rhea-AI Filing Summary

Clene Inc. reported insider selling of common stock by a 10% owner in December 2025. The Form 4 shows a series of open-market sales coded "S" from 12/03/2025 through 12/18/2025, with individual trades ranging from 2,884 to 72,748 shares at prices between $5.70 and $7.86 per share. All transactions involved Clene common stock held indirectly through Symbiosis II, LLC.

After these sales, the reporting person beneficially owned 393,150 shares of Clene common stock, held indirectly via Symbiosis II, LLC as of 12/18/2025. No derivative securities transactions were reported, as the derivative securities table is blank.

Insider Trade Summary

Net Seller: 257,795 shares

Net Sell 12 txns

Insider Ugwumba Chidozie

Role 10% Owner

Sold 257,795 shs ($1.73M)

Type	Security	Shares	Price	Value
Sale	Common Stock	5,816	$6.33	$37K
Sale	Common Stock	2,884	$6.61	$19K
Sale	Common Stock	7,030	$6.31	$44K
Sale	Common Stock	10,580	$6.49	$69K
Sale	Common Stock	7,603	$6.79	$52K
Sale	Common Stock	10,907	$6.81	$74K
Sale	Common Stock	9,921	$6.42	$64K
Sale	Common Stock	15,031	$5.95	$89K
Sale	Common Stock	21,463	$5.70	$122K
Sale	Common Stock	37,235	$5.94	$221K
Sale	Common Stock	72,748	$6.73	$490K
Sale	Common Stock	56,577	$7.86	$445K

Holdings After Transaction: Common Stock — 393,150 shares (Indirect, By Symbiosis II, LLC)

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider activity did Clene Inc. (CLNN) disclose in this Form 4?

The filing discloses that a 10% owner of Clene Inc. reported multiple open-market sales of Clene common stock in December 2025, all coded as sales ("S") in the non-derivative securities table.

Over what dates were CLNN shares sold and at what price range?

The reported sales of Clene Inc. common stock occurred from 12/03/2025 through 12/18/2025, at per-share prices ranging from $5.70 to $7.86.

How many Clene (CLNN) shares does the reporting person beneficially own after these transactions?

Following the reported transactions, the reporting person beneficially owned 393,150 shares of Clene common stock as of 12/18/2025, according to the Form 4.

Is the ownership of Clene Inc. (CLNN) shares direct or indirect in this Form 4?

The Form 4 shows the ownership form as Indirect (I), with the shares held by Symbiosis II, LLC on behalf of the reporting person.

What was the largest single reported sale of CLNN stock in this filing?

The largest individual sale reported was 72,748 shares of Clene common stock on 12/04/2025 at a price of $6.73 per share.

Were any derivative securities reported in this Clene (CLNN) Form 4?

No derivative securities transactions were reported. The table for derivative securities is present but contains no entries for acquired or disposed derivative instruments.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 12/18/2025 - 05:08 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Ugwumba Chidozie

(Last) (First) (Middle)

609 SW 8TH STREET

SUITE 510

(Street)

BENTONVILLE AR 72712

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Clene Inc. [ CLNN ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	X	10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
12/03/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	12/03/2025		S		56,577	D	$7.86	594,368	I	By Symbiosis II, LLC
Common Stock	12/04/2025		S		72,748	D	$6.73	521,620	I	By Symbiosis II, LLC
Common Stock	12/05/2025		S		37,235	D	$5.94	484,385	I	By Symbiosis II, LLC
Common Stock	12/08/2025		S		21,463	D	$5.7	462,922	I	By Symbiosis II, LLC
Common Stock	12/09/2025		S		15,031	D	$5.95	447,891	I	By Symbiosis II, LLC
Common Stock	12/10/2025		S		9,921	D	$6.42	437,970	I	By Symbiosis II, LLC
Common Stock	12/11/2025		S		10,907	D	$6.81	427,063	I	By Symbiosis II, LLC
Common Stock	12/12/2025		S		7,603	D	$6.79	419,460	I	By Symbiosis II, LLC
Common Stock	12/15/2025		S		10,580	D	$6.49	408,880	I	By Symbiosis II, LLC
Common Stock	12/16/2025		S		7,030	D	$6.31	401,850	I	By Symbiosis II, LLC
Common Stock	12/17/2025		S		2,884	D	$6.61	398,966	I	By Symbiosis II, LLC
Common Stock	12/18/2025		S		5,816	D	$6.33	393,150	I	By Symbiosis II, LLC

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

	/s/Chidozie Ugwumba	12/18/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.